In HFREF patients, sacubitril/valsartan, given at relatively low doses, does not lead to increased mortality or hospitalization

R De Vecchis, C Ariano, G Di Biase, M Noutsias - Herz, 2019 - search.proquest.com
Results Patients treated with sacubitril/valsartan in addition to beta-blocker and
mineralocorticoid receptor blocker were 68. Among them, 20 patients (29.4%), were …
被引用次数：7 相关文章

In HFREF patients, sacubitril/valsartan, given at relatively low doses, does not lead to increased mortality or hospitalization: A retrospective cohort study.

R De Vecchis, C Ariano, G Di Biase, M Noutsias - Herz, 2018 - europepmc.org
Results Patients treated with sacubitril/valsartan in addition to beta-blocker and
mineralocorticoid receptor blocker were 68. Among them, 20 patients (29.4%), were …

In HFREF patients, sacubitril/valsartan, given at relatively low doses, does not lead to increased mortality or hospitalization: A retrospective cohort study

R De Vecchis, C Ariano, G Di Biase, M Noutsias - Herz, 2019 - pubmed.ncbi.nlm.nih.gov
Introduction In heart failure with reduced left ventricular ejection fraction (HFREF) patients,
the dosage of sacubitril/valsartan is modulated according to a gradual increase regimen …